Asian Currencies Trade Sideways as Dollar Weakens Ahead of Key U.S. Data 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Dollar Holds Firm Ahead of Global Central Bank Decisions as Yen, Sterling and Euro React 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Bank of Japan Poised for Historic Rate Hike as Inflation Pressures Persist 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Chinese Robotaxi Stocks Rally as Tesla Boosts Autonomous Driving Optimism 
South Korea's SK Chemicals has partnered with AstraZeneca's Korean affiliate in a contract manufacturing organization (CMO) agreement. SK Chemicals will produce and globally distribute Sidapvia, a new treatment for type 2 diabetes, combining leading active ingredients dapagliflozin and sitagliptin.
Under this agreement, SK Chemicals will be responsible for the manufacturing and global distribution of Sidapvia, a groundbreaking combination of Forxig (dapagliflozin) and sitagliptin. Sidapvia is indicated for adults aged 18 and older with type 2 diabetes, a condition characterized by improper insulin function and high blood sugar levels.
SK Chemicals and AstraZeneca have jointly developed this promising diabetes treatment. While SK Chemicals focuses on manufacturing and distribution, AstraZeneca will be the marketing authorization holder (MAH). They will handle country-specific licensing and marketing efforts, and South Korea has already granted licensing for Sidapvia, making it the first country to do so.
Sidapvia combines two active ingredients, Forxiga and sitagliptin, globally recognized as a leading SGLT-2 inhibitor and top-selling DPP-4 inhibitor. These ingredients work through different mechanisms of action to effectively lower blood glucose levels, offering a viable option for managing complications among diabetic patients.
Ahn Jae-hyun, the CEO of SK Chemicals, expressed utmost confidence in the company's pharmaceutical technology and production capabilities. These capabilities have paved the way for the supply of medicines to numerous countries, and Ahn emphasized the company's plans to foster diverse collaboration opportunities.
The collaboration between SK Chemicals and AstraZeneca began in early 2020, with AstraZeneca providing SK Chemicals with active pharmaceutical ingredients (APIs) and funding research for diabetes treatment development. Subsequently, SK Chemicals took over product research and development and conducted domestic clinical trials. With this new agreement as a starting point, SK Chemicals aims to expand the supply of Sidapvia in Korea and the global market.
This collaboration marks a significant milestone for SK Chemicals and AstraZeneca, solidifying their commitment to advancing diabetes treatment and improving the lives of millions of patients worldwide.
